Multiple Sclerosis - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 812 pages report, published by Global Markets Direct

Keywords : Multiple Sclerosis Therapeutic Products under Development, Key Players in Multiple Sclerosis Therapeutics, Multiple Sclerosis Pipeline Overview, Multiple Sclerosis Pipeline, Multiple Sclerosis Pipeline Assessment

Report ThumbnailJune-2017
Multiple Sclerosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 30, 32, 1, 168, 34 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 47 and 2 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Multiple Sclerosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Multiple Sclerosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H1 2017
  • Multiple Sclerosis - Pipeline by 4D Pharma PLC, H1 2017
  • Multiple Sclerosis - Pipeline by AB Science SA, H1 2017
  • Multiple Sclerosis - Pipeline by AbbVie Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Abion Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Ablynx NV, H1 2017
  • Multiple Sclerosis - Pipeline by Abzena Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Actelion Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H1 2017
  • Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2017
  • Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H1 2017
  • Multiple Sclerosis - Pipeline by Alkermes Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Allergan Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Alvotech Iceland, H1 2017
  • Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H1 2017
  • Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Aphios Corp, H1 2017
  • Multiple Sclerosis - Pipeline by Apitope International NV, H1 2017
  • Multiple Sclerosis - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Argos Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Arven Ilac, H1 2017
  • Multiple Sclerosis - Pipeline by Asterias Biotherapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by AstraZeneca Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Athersys Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H1 2017
  • Multiple Sclerosis - Pipeline by Axxam SpA, H1 2017
  • Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by BioApex sro, H1 2017
  • Multiple Sclerosis - Pipeline by Biocad, H1 2017
  • Multiple Sclerosis - Pipeline by Biocon Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Biogen Inc, H1 2017
  • Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H1 2017
  • Multiple Sclerosis - Pipeline by Bionovis SA, H1 2017
  • Multiple Sclerosis - Pipeline by Bionure Farma SL, H1 2017
  • Multiple Sclerosis - Pipeline by Biovista Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H1 2017
  • Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Celgene Corp, H1 2017
  • Multiple Sclerosis - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
  • Multiple Sclerosis - Pipeline by Cinnagen Co, H1 2017
  • Multiple Sclerosis - Pipeline by Cognosci Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Commence Bio Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Compugen Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Multiple Sclerosis - Pipeline by CuraVac Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Cyxone AB, H1 2017
  • Multiple Sclerosis - Pipeline by DanDrit Biotech A/S, H1 2017
  • Multiple Sclerosis - Pipeline by Denceptor Therapeutics Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Eisai Co Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Eli Lilly and Company, H1 2017
  • Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Evotec AG, H1 2017
  • Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Flex Pharma Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Forward Pharma A/S, H1 2017
  • Multiple Sclerosis - Pipeline by FPRT Bio Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Gemac SA, H1 2017
  • Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
  • Multiple Sclerosis - Pipeline by GeNeuro SA, H1 2017
  • Multiple Sclerosis - Pipeline by Genzyme Corp, H1 2017
  • Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Glialogix Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Hansa Medical AB, H1 2017
  • Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Humabs BioMed SA, H1 2017
  • Multiple Sclerosis - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Immune Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Immungenetics AG, H1 2017
  • Multiple Sclerosis - Pipeline by Immunwork Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Inception Sciences Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Kadimastem Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H1 2017
  • Multiple Sclerosis - Pipeline by KAHR medical Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Kancera AB, H1 2017
  • Multiple Sclerosis - Pipeline by Karo Pharma AB, H1 2017
  • Multiple Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by KPI Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Multiple Sclerosis - Pipeline by LFB SA, H1 2017
  • Multiple Sclerosis - Pipeline by Lipocure Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by MacroGenics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals LLC, H1 2017
  • Multiple Sclerosis - Pipeline by MedAnnex Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by MedDay SA, H1 2017
  • Multiple Sclerosis - Pipeline by Medestea Research & Production SpA, H1 2017
  • Multiple Sclerosis - Pipeline by MedImmune LLC, H1 2017
  • Multiple Sclerosis - Pipeline by Merck KGaA, H1 2017
  • Multiple Sclerosis - Pipeline by Meta-IQ ApS, H1 2017
  • Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Mitotech SA, H1 2017
  • Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
  • Multiple Sclerosis - Pipeline by Mochida Pharmaceutical Co Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by MorphoSys AG, H1 2017
  • Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Neuralstem Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Neurofx Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Neuronax SAS, H1 2017
  • Multiple Sclerosis - Pipeline by New World Laboratories Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Novartis AG, H1 2017
  • Multiple Sclerosis - Pipeline by Nuevolution AB, H1 2017
  • Multiple Sclerosis - Pipeline by Numab Innovation AG, H1 2017
  • Multiple Sclerosis - Pipeline by Ogeda SA, H1 2017
  • Multiple Sclerosis - Pipeline by Omeros Corp, H1 2017
  • Multiple Sclerosis - Pipeline by OncoImmune Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Opexa Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H1 2017
  • Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H1 2017
  • Multiple Sclerosis - Pipeline by Pangen Biotech Inc., H1 2017
  • Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Pfenex Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Pfizer Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Pharmaxis Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by ProNoxis AB, H1 2017
  • Multiple Sclerosis - Pipeline by Prothena Corp Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Quimatryx SL, H1 2017
  • Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H1 2017
  • Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Regenesance BV, H1 2017
  • Multiple Sclerosis - Pipeline by Renovo Neural Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Resverlogix Corp, H1 2017
  • Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Rock Creek Pharmaceuticals Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H1 2017
  • Multiple Sclerosis - Pipeline by SanBio Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2017
  • Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Spherium Biomed SL, H1 2017
  • Multiple Sclerosis - Pipeline by Symic Biomedical Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Synthon Holdings BV, H1 2017
  • Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by TikoMed AB, H1 2017
  • Multiple Sclerosis - Pipeline by Tiziana Life Sciences Plc, H1 2017
  • Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2017
  • Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2017
  • Multiple Sclerosis - Pipeline by TxCell SA, H1 2017
  • Multiple Sclerosis - Pipeline by Vaccinex Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H1 2017
  • Multiple Sclerosis - Pipeline by Vicore Pharma AB, H1 2017
  • Multiple Sclerosis - Pipeline by viDA Therapeutics Inc, H1 2017
  • Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H1 2017
  • Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
  • Multiple Sclerosis - Pipeline by Xenetic Biosciences Inc, H1 2017
  • Multiple Sclerosis - Pipeline by XL-protein GmbH, H1 2017
  • Multiple Sclerosis - Pipeline by Yungjin Pharm Co Ltd, H1 2017
  • Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Multiple Sclerosis - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Multiple Sclerosis - Discontinued Products, H1 2017
  • Multiple Sclerosis - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Multiple Sclerosis - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Table of Contents
  • Table of Contents 2
  • Introduction 9
  • Multiple Sclerosis - Overview 10
  • Multiple Sclerosis - Therapeutics Development 11
  • Multiple Sclerosis - Therapeutics Assessment 48
  • Multiple Sclerosis - Companies Involved in Therapeutics Development 70
  • Multiple Sclerosis - Drug Profiles 160
  • Multiple Sclerosis - Dormant Projects 746
  • Multiple Sclerosis - Discontinued Products 763
  • Multiple Sclerosis - Product Development Milestones 766
  • Appendix 778

Please select a license type

Share

Related Products

Global Markets DirectMultiple Sclerosis - Pipeline Review, H1 2017Product ThumbnailMultiple Sclerosis - Pipeline Review, H1 2017, Industry ReportProduct #: 829008
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved